scispace - formally typeset
Search or ask a question
Author

Xiaoyuan Chen

Bio: Xiaoyuan Chen is an academic researcher from National University of Singapore. The author has contributed to research in topics: Physics & Photothermal therapy. The author has an hindex of 149, co-authored 994 publications receiving 89870 citations. Previous affiliations of Xiaoyuan Chen include Brown University & University of Southern California.


Papers
More filters
Patent
21 Mar 2019
TL;DR: In this paper, the authors present an invention to a compound of Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof.
Abstract: The present invention is directed to a compound of Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula III wherein the definitions of R1-R12 and L1-L4 are provided in the disclosure, wherein R13 is a chelating group comprising 177Lu, and wherein R14 is a peptide. The compounds of Formula I may be covalently bonded to a peptide via a linker to provide a compound of Formula III and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.

4 citations

Journal ArticleDOI
TL;DR: VEGF(121)/rGel appears to be an effective therapeutic agent causing focused damage to tumor vasculature with minimal toxic effects to normal organs and is an excellent candidate for further clinical development.

3 citations

Journal Article
TL;DR: In this paper, the authors developed a novel 18F-based PET radiopharmaceutical, [18F]FPPRGD2 (FDA eIND 104150), based on the dimeric RGD peptide sequence, which targets the αvβ3 integrin.
Abstract: 1433 Objectives Angiogenesis is essential for tumor growth. The expression of αvβ3 on capillary cells has a key role in this process. We have developed a novel 18F-based PET radiopharmaceutical, [18F]FPPRGD2 (FDA eIND 104150), based on the dimeric RGD peptide sequence, which targets the αvβ3 integrin. We present data on the first people imaged with this tracer. Methods Five healthy volunteers (mean age: 42) were recruited. Three PET and 1 PET/CT scans were obtained up to 3 hours post-injection (dose: 9.5 ± 3.4 mCi; specific activity: 1200 ± 714 mCi/umol) using a GE Discovery LS PET/CT scanner. During this time, vitals, EKGs, and blood samples were obtained at regular intervals. The blood was used to calculate time activity curves and to ensure stability of the tracer and lab values. The imaging data was used to evaluate biodistribution, as well as for dosimetry calculations using OLINDA. Results The radiopharmaceutical was well tolerated with no alterations in vitals, EKGs, or lab values noted. There was stable distribution in all patients with primary clearance through the kidneys, as well as the liver, spleen, and bowel. Only minimal uptake was seen elsewhere. Time activity curves showed rapid clearance from the vasculature within 30 minutes, with most of the activity in the plasma. Dosimetry (units are rem/mCi) showed the principal organs to be the urinary bladder (0.863) (bladder voiding model), lower large intestine (0.529), kidneys (0.360), and spleen (0.250). Conclusions [18F]FPPRGD2 is safe, with desirable pharmacokinetic and biodistribution characteristics for imaging angiogenesis (αvβ3-integrin expression), especially in the head, neck, thorax and extremities. Testing of [18F]FPPRGD2 in patients with cancers is planned. Based on these results, this radiopharmaceutical would be optimal for brain, lung, and breast cancers, but may also be useful for other regions and non-imaging applications

3 citations

Journal ArticleDOI
TL;DR: The proposed EMD-LSTM independent forecasting model is able to identify the characteristics of each frequency component of electricity consumption data, and its error is reduced by about 15% on average, thus achieving the goal of improving the accuracy of load forecasting in short-term electricity consumption forecasting scenarios.
Abstract: Accurate electricity consumption forecasting can improve the efficiency of grid dispatching and effectively guarantee the stable operation of the power system. Electricity consumption forecasting is important for the analysis of customer-side electricity consumption behavior, but the instability of electricity consumption sequences poses difficulties for forecasting. Therefore, an improved combination of integrated empirical modal decomposition (EMD) and long short-term memory network (LSTM) is proposed for customer-side electricity consumption forecasting. This paper starts from the idea of blind source separation and independent prediction, and firstly decomposes the original electricity consumption data into several inherent mode functions (IMFs) with different frequencies and amplitudes by empirical modal decomposition (EMD), and then uses LSTM to extract features and make temporal prediction for each IMF component one by one with machine learning intelligent algorithm., and finally obtains end-user-side short-term electricity consumption prediction results by accumulating multiple target prediction results. Compared with direct forecasting, the proposed EMD-LSTM independent forecasting model is able to identify the characteristics of each frequency component of electricity consumption data, and its error is reduced by about 15% on average, thus achieving the goal of improving the accuracy of load forecasting in short-term electricity consumption forecasting scenarios.

3 citations

Journal ArticleDOI
TL;DR: In this article , a search for CP violation in Λ decay is performed in the difference between CP-odd decay parameters α = 0.0036±0.0024 and α = −0.7519±1.0012.
Abstract: Based on 10 billion J/ψ events collected at the BESIII experiment, a search for CP violation in Λ decay is performed in the difference between CP-odd decay parameters α_{-} for Λ→pπ^{-} and α_{+} for Λ[over ¯]→p[over ¯]π^{+} by using the process e^{+}e^{-}→J/ψ→ΛΛ[over ¯]. With a five-dimensional fit to the full angular distributions of the daughter baryon, the most precise values for the decay parameters are determined to be α_{-}=0.7519±0.0036±0.0024 and α_{+}=-0.7559±0.0036±0.0030, respectively. The Λ and Λ[over ¯] averaged value of the decay parameter is extracted to be α_{avg}=0.7542±0.0010±0.0024 with unprecedented accuracy. The CP asymmetry A_{CP}=(α_{-}+α_{+})/(α_{-}-α_{+}) is determined to be -0.0025±0.0046±0.0012, which is one of the most precise measurements in the baryon sector. The reported results for the decay parameter will play an important role in the studies of the polarizations and CP violations for the strange, charmed and beauty baryons.

3 citations


Cited by
More filters
Journal ArticleDOI

[...]

08 Dec 2001-BMJ
TL;DR: There is, I think, something ethereal about i —the square root of minus one, which seems an odd beast at that time—an intruder hovering on the edge of reality.
Abstract: There is, I think, something ethereal about i —the square root of minus one. I remember first hearing about it at school. It seemed an odd beast at that time—an intruder hovering on the edge of reality. Usually familiarity dulls this sense of the bizarre, but in the case of i it was the reverse: over the years the sense of its surreal nature intensified. It seemed that it was impossible to write mathematics that described the real world in …

33,785 citations

28 Jul 2005
TL;DR: PfPMP1)与感染红细胞、树突状组胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作�ly.
Abstract: 抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1(PfPMP1)与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员,通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

18,940 citations

Journal ArticleDOI
TL;DR: The interest in nanoscale materials stems from the fact that new properties are acquired at this length scale and, equally important, that these properties are equally important.
Abstract: The interest in nanoscale materials stems from the fact that new properties are acquired at this length scale and, equally important, that these properties * To whom correspondence should be addressed. Phone, 404-8940292; fax, 404-894-0294; e-mail, mostafa.el-sayed@ chemistry.gatech.edu. † Case Western Reserve UniversitysMillis 2258. ‡ Phone, 216-368-5918; fax, 216-368-3006; e-mail, burda@case.edu. § Georgia Institute of Technology. 1025 Chem. Rev. 2005, 105, 1025−1102

6,852 citations